ERBB2 and adrenal gland pheochromocytoma: Biomarker analysis revealed significant molecular distinctions: PCC patients had lower Her‐2 positivity (2.08% vs. 25.00%, p = 0.001) and a higher rate of E‐cadherin negativity (23.08% vs. 0.00%, p = 0.049), indicating unique molecular characteristics compared to non‐PCC patients.